The Down HER2-Low: Updates in Metastatic Breast Cancer Treatment
This presentation will provide an overview of new treatment options in metastatic breast cancer. Pharmacists will learn about the therapeutic subgroups within breast cancer, including the newest subtype “Her-2 Low.” There will be an in-depth review of sacituzumab govitecan and fam-trastuzumab deruxtecan including mechanism, pharmacokinetics, and adverse drug effects. Primary literature will be presented with focus on baseline characteristics of patient population, efficacy, and safety outcomes.
This activity is intended for pharmacists and pharmacy technicians.
Pharmacists learning objectives
- Describe the epidemiology and pathogenesis of the therapeutic subgroups of breast cancer patients.
- Understand the mechanism of action, pharmacokinetics, and adverse effects of newly approved agents used in metastatic breast cancer.
- Utilize primary literature to support the use and place in therapy for newly approved agents for the treatment of metastatic breast cancer.
- Recommend supportive care strategies for adverse drug reactions to cancer treatment in patients with metastatic breast cancer.
Pharmacy technician learning objectives
At the conclusion of this activity, pharmacy technicians should be able to:
- Understand the preparation and administration of newly approved agents for the treatment of metastatic breast cancer.
- Recognize the difference in trastuzumab based products.
Caroline Baer, PharmD
PGY2 Oncology Pharmacy Resident
Christine Marie McNamara Garcia, PharmD, BCOP
Clinical Pharmacy Specialist- Oncology
Natalie Tucker, PharmD, BCCCP
Clinical Pharmacy Specialist- Neurocritical Care
Identification, Mitigation, and Disclosure of Relevant Financial Relationships
As an accredited provider of continuing education, Vizient, Inc. is dedicated to ensuring this activity presents learners with only accurate, balanced, scientifically justified recommendations, and is free from promotion, marketing, and commercial bias. In accordance with The Standards for Integrity and Independence in Accredited Continuing Education, all planners, faculty, and others in control of the educational content have disclosed the absence or existence of all financial relationships (of any dollar amount) with ineligible companies within the past 24 months.
It is Vizient’s policy that owners and employees of ineligible companies, and any individuals who refuse to disclose the absence or existence of financial relationships with any ineligible companies are disqualified from participating as planners or faculty.
Disclosure of Financial Relationships:
Absence of Relevant Financial Relationships
Vizient, Inc., Jointly Accredited for Interprofessional Continuing Education, defines companies to be ineligible as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
An individual is considered to have a relevant financial relationship if the educational content an individual can control is related to the business lines or products of the ineligible company.
No one in a position to control the content of this educational activity have relevant financial relationships with ineligible companies.
Statement of content validity
Vizient, Inc. educational activities are intended to assist healthcare teams advance their professional responsibilities in accordance with the definition of continuing education. It is the policy of Vizient, Inc. to review and ensure that all content and recommendations for patient care within accredited CE is evidenced-based, based on current science and clinical reasoning while ensuring the content is fair and balanced. All recommendations must conform to the generally accepted standards of experimental design, data collection, analysis, and interpretation. Vizient, Inc. does not permit accredited continuing education if it advocates for unscientific approaches to diagnosis or therapy, or if the education promotes recommendations, treatment, or manners of practicing healthcare that are determined to have risks or dangers that outweigh the benefits or are known to be ineffective in the treatment of patients.
FDA off-label/unapproved usage
Faculty/Presenters are required to identify any new and evolving topics for which there is a lower/absence of evidence base. This is to ensure that our content does not advocate for, or promote, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning. Faculty/Presenters are required to disclose any discussion of (1) off-label/unapproved or investigational uses of FDA approved commercial products or devices and/or (2) products or devices not yet approved in the United States.
Disclaimer: The education provided through this activity is for continuing education purposes only. The views and opinions expressed in this activity are those of the faculty/presenters and do not necessarily reflect the views of Vizient, Inc.
Joint Accreditation Statement:
In support of improving patient care, this activity has been planned and implemented by Vizient, Inc. and Ochsner. Vizient, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Vizient, Inc. designates this activity for a maximum of 1.0 ACPE credit hours.
Vizient, Inc. will award all other healthcare professionals who successfully complete the activity a Certificate of Participation indicating the maximum credits available. Various state license boards and credentialing bodies accept certificates of participation from accredited CE activities to meet CE requirements for license renewals and re-certification. It is the responsibility of the participant to contact their state licensing board and/or certifying body for verification on credit eligibility reciprocity.
- 1.00 ACPE Pharmacist
- 1.00 ACPE Pharmacy Technician
- 1.00 General CE – Attendance